TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31967283

Group type: EXPERIMENTAL
Intervention: Two‐point group (local anesthetic at 'anesthesia point', alcohol at 'lesion point')
Number of subjects: 30

Group type: COMPARATOR
Intervention: Single‐point group (alcohol and local anesthetic at the same point)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Two‐point group
Number of subjects: 30
Study: 31525829

Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage (MLD) with Compression Bandage (CB)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic Compression (IPC) with Compression Bandage (CB)
Number of subjects: 46
Study: 27384328

Group type: EXPERIMENTAL
Intervention: WBV
Number of subjects: 28
Study: 26607745

Group type: EXPERIMENTAL
Intervention: Pronator quadratus (PQ) repair
Number of subjects: 60

Group type: COMPARATOR
Intervention: No repair (Control)
Number of subjects: 60
Study: 23812862

Group type: EXPERIMENTAL
Intervention: Intravenous interferon (IFN) administered during the anhepatic phase of liver transplantation, along with weight-based ribavirin and subcutaneous IFN at time of incision.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no intravenous interferon).
Number of subjects: 15
Study: 20932360

Group type: EXPERIMENTAL
Intervention: Stepped care cognitive behaviour therapy (CBT) - 10 sessions
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Stepped care cognitive behaviour therapy (CBT) - 5 additional sessions (second phase)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Stepped care cognitive behaviour therapy (CBT) - 5 additional sessions (third phase)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Stepped care cognitive behaviour therapy (CBT)
Number of subjects: 133
Study: 19031371

Group type: EXPERIMENTAL
Intervention: Individualized target heart rate calculated corresponding to an intensity of 60% to 80% of calculated VO(2)max (97 to 137 beats per minute)
Number of subjects: 61
Study: 17319037

Group type: COMPARATOR
Intervention: Topical clobetasol propionate 0.05% cream
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Topical tazarotene 0.1% cream
Number of subjects: 36
Study: 15525784

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (0.26 mA) applied during SWS-rich sleep for 30 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anodal tDCS during wake retention interval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0
Study: 11251629

Group type: EXPERIMENTAL
Intervention: SR 48968C (100 mg orally once daily for 9 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10050402

Group type: EXPERIMENTAL
Intervention: nonspecific combined detoxication
Number of subjects: 176
Study: 7983293

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Previous episodes of depression
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Follow-up period
Number of subjects: 94
Study: 30777117

Group type: EXPERIMENTAL
Intervention: Xuebijing (XBJ) injection
Number of subjects: 300

Group type: COMPARATOR
Intervention: 0.9% NaCl injection (placebo control)
Number of subjects: 300
Study: 29078800

Group type: EXPERIMENTAL
Intervention: 12-week exercise programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not informed)
Number of subjects: 0
Study: 26175332

Group type: EXPERIMENTAL
Intervention: Ethyl-eicosapentaenoic acid (EPA)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 25607558

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine emulsion (CsAE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Emulsion (vehicle)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Untreated nails
Number of subjects: 24
Study: 21196426

Group type: EXPERIMENTAL
Intervention: Walking outdoors near roadways
Number of subjects: 0

Group type: COMPARATOR
Intervention: Walking indoors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSTM1 gene deletion
Number of subjects: 0
Study: 19561372

Group type: EXPERIMENTAL
Intervention: Standard cycle ergometry
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Strength cycle ergometry
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study: 16941406

Group type: EXPERIMENTAL
Intervention: 100 mg Aspirin (ASA) once daily
Number of subjects: 250

Group type: COMPARATOR
Intervention: 75 mg Clopidogrel once daily
Number of subjects: 250
Study: 15385014

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine 1 mg x kg(‐1) (group K)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine 0.5 mg x kg(‐1) plus clonidine 1 microg x kg(‐1) (group KC)
Number of subjects: 44
Study: 11222185

Group type: EXPERIMENTAL
Intervention: 1.5 mL/kg of low osmolality contrast medium
Number of subjects: 457

Group type: COMPARATOR
Intervention: 150 mL of low osmolality contrast medium
Number of subjects: 457

Group type: COMPARATOR
Intervention: 100 mL of low osmolality contrast medium
Number of subjects: 457
Study: 9444494

Group type: EXPERIMENTAL
Intervention: Trimipramine and adjunct bright-light therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Trimipramine monotherapy
Number of subjects: 28
Study: 7506176

Group type: EXPERIMENTAL
Intervention: nimesulide (50mg granules twice daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: lysine-aspirin (360mg granules twice daily)
Number of subjects: 70
Study: 3566994

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 50
Study: 31755374

Group type: EXPERIMENTAL
Intervention: Differential Learning (DL)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Contextual Interference (CI)
Number of subjects: 32
Study: 30004565

Group type: EXPERIMENTAL
Intervention: Early functional exercises of passive and autonomic activities
Number of subjects: 92
Study: 27852283

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (0.67 mg/m2/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 24114421

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5% gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intense pulsed light therapy (IPL)
Number of subjects: 50
Study: 22819275

Group type: EXPERIMENTAL
Intervention: Lean children
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 162
Study: 20546545

Group type: EXPERIMENTAL
Intervention: Recreational football (FG)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Running (RG)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 28
Study: 18465391

Group type: EXPERIMENTAL
Intervention: BB&B programme
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (no BB&B programme)
Number of subjects: 162
Study: 15823625

Group type: EXPERIMENTAL
Intervention: ACE inhibitor moexipril added to combination therapy
Number of subjects: 420
Study: 12094189

Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 234

Group type: COMPARATOR
Intervention: Diltiazem CD
Number of subjects: 234
Study: 10511936

Group type: EXPERIMENTAL
Intervention: Silicone intraocular lenses (Allergan SI‐40NB)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Poly(methyl methacrylate) intraocular lenses (Pharmacia 812 C)
Number of subjects: 62
Study: 7738683

Group type: EXPERIMENTAL
Intervention: Initial fat mass and fat mass slope plus either vitamin A, carotene, fiber, magnesium, or phosphorus
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fat mass slope plus sodium
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Energy intake
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Initial fat mass
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 66
Study: 2045727

Group type: EXPERIMENTAL
Intervention: Methylphenidate (three levels of dosage)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 6768443

Group type: EXPERIMENTAL
Intervention: Thiotepa weekly for one year (N = 90)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No further therapy (Control group, N = 77)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Thiotepa treatment in negative node patients less than 55 years old
Number of subjects: 90
Study: 31591940

Group type: EXPERIMENTAL
Intervention: Teprenone 150 mg/day
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 29351138

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 27835981

Group type: EXPERIMENTAL
Intervention: Night Shift video game intervention
Number of subjects: 366

Group type: COMPARATOR
Intervention: Educational program
Number of subjects: 366
Study: 24858141

Group type: EXPERIMENTAL
Intervention: 200 IU of vitamin D
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 400 IU of vitamin D
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 600 IU of vitamin D
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 800 IU of vitamin D
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control (no vitamin D supplementation)
Number of subjects: 213
Study: 22622598

Group type: EXPERIMENTAL
Intervention: Chicago Parent Program (CPP)
Number of subjects: 504
Study: 19638336

Group type: EXPERIMENTAL
Intervention: 0.001% bFGF
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 0.01% bFGF
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 17889680

Group type: EXPERIMENTAL
Intervention: Slow injection (2.0 mL lidocaine with 1:80,000 epinephrine over 60 seconds)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Rapid injection (2.0 mL lidocaine with 1:80,000 epinephrine over 15 seconds)
Number of subjects: 38
Study: 15547121

Group type: EXPERIMENTAL
Intervention: Foot orthoses (prefabricated)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foot orthoses (customized)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Foot orthoses (prefabricated or customized)
Number of subjects: 0
Study: 11732862

Group type: EXPERIMENTAL
Intervention: IL-12 and IL-15 levels in patients' serum
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Soluble CD26 levels in patients' serum
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Adenosine deaminase levels in patients' serum
Number of subjects: 35
Study: 9205762

Group type: EXPERIMENTAL
Intervention: Ebrotidine 400 mg daily
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ebrotidine 600 mg daily
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ebrotidine 800 mg daily
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ebrotidine 200 mg daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 7963150

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (2 sprays per nostril once daily)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (2 sprays per nostril twice daily)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 3598772

Group type: COMPARATOR
Intervention: 38 kcal/kg/d nonprotein energy (Group 1)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 64 kcal/kg/d nonprotein energy (Group 2)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 64 kcal/kg/d nonprotein energy plus 1 to 2 g/kg/d crystalline amino acids (Group 3)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: All groups (1, 2, and 3)
Number of subjects: 19
Study: 28988339

Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Psychoeducation (PEP)
Number of subjects: 180
Study: 26764260

Group type: EXPERIMENTAL
Intervention: Disease activity-guided dose optimisation strategy of adalimumab or etanercept (TNFi)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 180
Study: 24655439

Group type: EXPERIMENTAL
Intervention: Tailored implementation programs for chronic diseases
Number of subjects: 0

Group type: COMPARATOR
Intervention: Qualitative analysis in Norway
Number of subjects: 0
Study: 22542362

Group type: EXPERIMENTAL
Intervention: Eculizumab therapy
Number of subjects: 11
Study: 20056719

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Self-Management (SM)
Number of subjects: 171
Study: 18317625

Group type: EXPERIMENTAL
Intervention: Low-calorie diet plus orlistat 120 mg three times daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-calorie diet alone
Number of subjects: 30
Study: 16046191

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery (GBP)
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Control group (GBP seeking individuals denied surgery)
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Control group (severely obese not seeking GBP)
Number of subjects: 1156
Study: 11945148

Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg/day)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Control
Number of subjects: 496
Study: 10333912

Group type: EXPERIMENTAL
Intervention: Metformin plus repaglinide
Number of subjects: 83

Group type: COMPARATOR
Intervention: Repaglinide monotherapy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Metformin monotherapy
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Repaglinide (combined therapy)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Repaglinide (monotherapy)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Combined therapy (metformin and repaglinide)
Number of subjects: 83
Study: 7793116

Group type: EXPERIMENTAL
Intervention: Continuous s.c. infusion of AVP (7.5 micrograms/d) for one week
Number of subjects: 5

Group type: COMPARATOR
Intervention: 0.9% NaCl-solution (placebo)
Number of subjects: 5
Study: 2025476

Group type: EXPERIMENTAL
Intervention: Alfentanil-propofol anaesthesia (group II, n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alfentanil-nitrous oxide anaesthesia (group I, n = 15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propofol 6 mg kg‐1 h‐1 after 90 min of nitrous oxide 66% in oxygen
Number of subjects: 30
Study: 7344590

Group type: EXPERIMENTAL
Intervention: Acebutolol 400mg or more daily (once daily dosing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acebutolol 400mg or more daily (twice daily dosing)
Number of subjects: 0
Study: 30726107

Group type: EXPERIMENTAL
Intervention: High-Intensity Continuous Running (HICR)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Running (MICR)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 20
Study: 28241159

Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (LT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Dim-Red Light Therapy (Control)
Number of subjects: 31
Study: 25399699

Group type: EXPERIMENTAL
Intervention: 8 weeks of manualized training in dialogic book-sharing
Number of subjects: 91

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 91
Study: 24368615

Group type: EXPERIMENTAL
Intervention: Group-led walking (weeks 1 to 10)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Independent walking (weeks 11 to 16)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 75
Study: 22584195

Group type: EXPERIMENTAL
Intervention: Cat exposure
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Daycare exposure
Number of subjects: 299

Group type: COMPARATOR
Intervention: Maternal asthma
Number of subjects: 299

Group type: COMPARATOR
Intervention: Baseline body mass index
Number of subjects: 299

Group type: COMPARATOR
Intervention: Specific immunoglobulin E to house-dust mix at 3 years
Number of subjects: 299

Group type: COMPARATOR
Intervention: Dog, mouse, rat, and cockroach exposures
Number of subjects: 299
Study: 19350472

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Experimental add-on therapy with D-Cycloserine
Number of subjects: 360
Study: 17306703

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (0.75 microg/kg every 2 weeks for 26 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 14985175

Group type: EXPERIMENTAL
Intervention: Red wine intake (300-350 ml, approximately two glasses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: White wine intake (300-350 ml, approximately two glasses)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no wine consumption)
Number of subjects: 24
Study: 11152852

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) plus estradiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9885068

Group type: EXPERIMENTAL
Intervention: Imaginary enactment
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Actual construction
Number of subjects: 4

Group type: COMPARATOR
Intervention: Visual examination
Number of subjects: 4

Group type: COMPARATOR
Intervention: Imagining construction
Number of subjects: 4
Study: 7730878

Group type: EXPERIMENTAL
Intervention: Low fat high fibre diet (LFHF)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Normal western diet (ND)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Low fat high fibre diet (LFHF) in women
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Low fat high fibre diet (LFHF) in men
Number of subjects: 201
Study: 3898645

Group type: EXPERIMENTAL
Intervention: Psychological biobehavioral treatment program
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 30
Study: 31985531

Group type: EXPERIMENTAL
Intervention: Serum transferrin
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Composite scores (model of end-stage liver disease, Glasgow alcoholic hepatitis score, discriminant function)
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Validation cohort
Number of subjects: 828
Study: 30350844

Group type: EXPERIMENTAL
Intervention: Policosanol + aspirin
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo + aspirin
Number of subjects: 142
Study: 27144494

Group type: COMPARATOR
Intervention: Placebo arm of a 10-week randomized controlled trial of atomoxetine
Number of subjects: 14

Group type: COMPARATOR
Intervention: 90% reliable change indices (RCIs) based on healthy adults
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 90% reliable change indices (RCIs) based on PD‐MCI sample
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Executive function tests
Number of subjects: 14
Study: 24667714

Group type: EXPERIMENTAL
Intervention: TargetPrint
Number of subjects: 800

Group type: COMPARATOR
Intervention: Local assessment
Number of subjects: 800
Study: 22608359

Group type: EXPERIMENTAL
Intervention: CoQ10 60 mg twice daily
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 20492039

Group type: EXPERIMENTAL
Intervention: Indoor gardening programme (8 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Regular care (control group)
Number of subjects: 53
Study: 18640458

Group type: EXPERIMENTAL
Intervention: AN1792 (Aβ42 immunisation)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 17492558

Group type: EXPERIMENTAL
Intervention: Bone tunnel fixation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Suture anchor
Number of subjects: 48
Study: 15319673

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (90 mg twice daily) + optimized background regimen
Number of subjects: 995

Group type: COMPARATOR
Intervention: Optimized background regimen alone
Number of subjects: 995
Study: 11044234

Group type: EXPERIMENTAL
Intervention: losartan 50 mg daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 9285079

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 1362671

Group type: EXPERIMENTAL
Intervention: Pen injector (Human NPH insulin in penfills)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Syringe (Human NPH insulin in vials)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pen injector
Number of subjects: 18

Group type: COMPARATOR
Intervention: Syringe
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 18
Study: 3516754

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 17-butyrate (Locoid) 0.1% fatty cream
Number of subjects: 30

Group type: COMPARATOR
Intervention: Desonide (Apolar) 0.1% ointment
Number of subjects: 30
Study: 30865051

Group type: EXPERIMENTAL
Intervention: Daily dosing arm of FTC/TDF-based PrEP
Number of subjects: 176

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 176
Study: 28343582

Group type: EXPERIMENTAL
Intervention: Cold application (+8°C) for 20 minutes
Number of subjects: 18

Group type: COMPARATOR
Intervention: Thermoneutral application (+32°C) for 20 minutes
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cold application (+8°C)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Thermoneutral application (+32°C)
Number of subjects: 18
Study: 26510664

Group type: EXPERIMENTAL
Intervention: Clostridium butyricum MIYAIRI (CBM) - 9 tablets orally once daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo - 9 tablets orally once daily
Number of subjects: 17
Study: 24613524

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccination (PPS)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Pneumococcal carriage with 19F or 23F prior to PPS immunization
Number of subjects: 230
Study: 22009018

Group type: EXPERIMENTAL
Intervention: Estimated time limit scale (ETL) for regulating exercise intensity
Number of subjects: 36
Study: 19746336

Group type: EXPERIMENTAL
Intervention: Group A (direct transfer to ward after assessment using the White and Song scoring system)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Group B (transfer to PACU before ward)
Number of subjects: 157
Study: 17518954

Group type: EXPERIMENTAL
Intervention: First premolar/canine-guided occlusion denture (CGD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lingualised occlusion denture (LOD)
Number of subjects: 20
Study: 15159414

Group type: EXPERIMENTAL
Intervention: Fludarabine plus mitoxantrone (FM)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 140